AbbVie Says Risankizumab More Effective Than Placebo For Crohn's Disease Management
May 24, 2016 at 12:14 PM EDT
AbbVie Inc (NYSE: ABBV) disclosed that it presented a proof of concept, Phase II trial in Crohn's disease with investigatory biologic ...